Pre-Day Highlights of ECTRIMS 2025
Direct from Barcelona, listen to Alvaro Cobo Calvo from the Multiple Sclerosis Center of Catalonia (Cemcat) and host Brett Drummond discuss the highlights of ECTRIMS 2025 Pre-Day, which is focused on ...
23 Syys 202517min
2024 Revisions of the McDonald Diagnostic Criteria: What Neurologists Need to Know
The 2024 Revisions of the McDonald Diagnostic Criteria for MS have been published in The Lancet Neurology. What do these changes mean for clinical practice? In this episode, we are joined by two autho...
19 Syys 202520min
Genetics and MS: Recent Discoveries and Future Directions
Genetics not only influence the risk of developing multiple sclerosis (MS), but also affect how the disease progresses and how patients respond to different treatments. Professor Philip De Jager, Chie...
8 Syys 202527min
The Expanding Role of Patient-Reported Outcomes in MS Research
Patient-reported outcomes (PROs) have become a critical tool for capturing the lived experience of multiple sclerosis (MS), offering a perspective that extends beyond traditional clinical and imaging ...
17 Heinä 202520min
Biomarkers in MS
Biomarkers are one of the most exciting and fast-evolving areas in multiple sclerosis research, offering promise for earlier diagnosis, accurate prognosis, and truly personalised treatment. Yet despit...
12 Kesä 202525min
BTK Inhibitors: The Tolebrutinib Trial Results
Over the past few years, the MS research community has been following developments in a new class of therapies called Bruton's tyrosine kinase inhibitors (BTKis). At ECTRIMS 2024, the results of two t...
21 Touko 202525min
The Role of Diet in Managing MS
What do the latest research findings tell us about the role diet can play in the management of multiple sclerosis (MS)? How should neurologists talk about diet with their patients? While people living...
24 Huhti 202528min
Autologous Haematopoietic Stem Cell Transplantation for MS
Autologous haematopoietic stem cell transplantation (AHSCT) has gained considerable attention in recent years as a treatment option for multiple sclerosis (MS). As long-term clinical trial data on AHS...
27 Maalis 202529min
